The short version of melanocortin receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-11. Anything still debated is marked as such rather than presented as settled.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Yeast is the microorganism that is responsible for fermentation in beer. Yeast metabolises the sugars extracted from grains, which produces alcohol and carbon dioxide, and thereby turns wort into beer. In addition to fermenting the beer, yeast influences the character and flavour. The dominant types of yeast used to make beer are Saccharomyces cerevisiae, known as ale yeast, and Saccharomyces pastorianus, known as lager yeast; Brettanomyces ferments lambics, and Torulaspora delbrueckii ferments Bavarian weissbier. Before the role of yeast in fermentation was understood, fermentation involved wild or airborne yeasts, and a few styles such as lambics still use this method today. Emil Christian Hansen, a Danish biochemist employed by the Carlsberg Laboratory, developed pure yeast cultures which were introduced into the Carlsberg brewery in 1883, and pure yeast strains are now the main fermenting source used worldwide.
Brian Niccol, chair and CEO of Starbucks Richard Allison, former CEO of Domino's Pizza Andrew Campion, COO of Nike, Inc. Beth Ford, CEO of Land O'Lakes Jørgen Vig Knudstorp, executive chairman of LEGO Group Marissa Mayer, former president and CEO of Yahoo! Neal Mohan, CEO of YouTube Dambisa Moyo, Co-principal of Versaca Investments Daniel Servitje, CEO of Grupo Bimbo Mike Sievert, former CEO of T-Mobile US Wei Zhang, former president of Alibaba Pictures Group Howard Schultz, president and former CEO of Starbucks
== Functions == The physiological action of RLN and its tandem duplicates (RLN1, INSL4, INSL6) and INSL3 has been quite well studied in humans and mouse models. They are primarily associated with reproductive functions, such as the relaxation of uterine musculature and of the pubic symphysis during labor (RLN1 & RLN2), the progression of spermatogenesis (INSL6) and possibly trophoblast development (INSL4) and testicular descent and germ cell survival (INSL3). INSL5 is produced by L-cells in the colon, plays a physiological role in food intake, and may regulate metabolism and energy balance. RLN3 is thought to function in neuroendocrine regulation, and is predominantly expressed in the nucleus incertus (NI) of the hindbrain and locally affects regions of the central nervous system (CNS) including those responsible for appetite and stress regulation. RLN3 has also been found to stimulate the hypothalamic-pituitary-gonadal (HPG) axis and hence affects levels of luteinizing hormone (LH) in the blood.
=== Lysine-depleted variants (LDVs) === Another strategy for site-specific amine conjugation to proteins is to replace lysine residues with arginine residues (LDVs). If all lysines are depleted then the only remaining free amine is at the amino terminus (N-terminus) of the protein. In the case where the protein is an antibody Fc domain, a recombinant LDV Fc can still be purified using protein A. LDV Fc proteins fused with short peptide targeting sequences can be used to deliver conjugated payloads, including nanoparticles, to specific cell surface proteins.
Sources: en.wikipedia.org
=== Guest appearances === Snobs (13 January 2000) – 1 episode Loose Women (16 September 2011, 1 March 2012, 26 April 2013, 3 October 2013, 24 February 2014, 4 February 2016, 4 March 2016, 3 March 2017, 6 April 2017, 7 September 2017, 2 March 2018, 27 June 2018, 11 February 2019, 20 February 2019, 19 March 2019, 6 August 2020) – 16 episodes I'm a Celebrity...Get Me Out of Here! NOW! (23–25 November 2011, 16 November 2015) – 4 episodes Peter Andre: My Life (14 December 2011) – 1 episode That Sunday Night Show (8 January 2012) – 1 episode Celebrity Juice (15 March 2012, 9 May 2013, 11 April 2019, 24 October 2019, 12 November 2020) – 5 episodes This Morning (30 March 2012, 2 April 2012, 4 April 2012, 31 August 2012, 19 September 2012, 18 January 2013, 5 April 2013, 19 April 2013, 24 April 2013, 28 November 2014, 3 December 2014, 4 December 2014, 13 May 2015, 5 February 2016, 4 July 2016, 2 August 2016, 30 April 2018, 1 October 2018, 7 January 2019, 23 January 2019, 4 February 2019, 11 February 2019, 14 August 2019, 18 December 2019, 28 June 2024) – 25 episodes The Big Quiz (15 April 2012) – 1 episode 8 Out of 10 Cats (15 June 2012, 25 January 2013, 28 January 2020) – 3 episodes Big Brother's Bit on the Side (4 July 2012, 28 July 2013, 13 May 2015, 16 June 2017) – 4 episodes Let's Do Lunch with Gino & Mel (29 August 2012) – 1 episode Celebrity Big Brother's Bit on the Side (6 September 2012, 9 January 2013, 1 September 2013, 19 August 2014, 29 January 2015, 2 February 2016, 4–5 February 2016, 1 August 2017) – 9 episodes Fake Reaction (3 January 2013) – 1 episode 8 Out of 10 Cats Does Deal or No Deal (4 January 2013) – 1 episode Food Glorious Food (24 April 2013) – 1 episode Sunday Side Up (29 December 2013) – 1 episode Who's Doing the Dishes? (3 October 2014) – 1 episode Phillip's Live 24-Hour TV Marathon (1 December 2014) – 1 episode Mel & Sue (14 January 2015) – 1 episode If Katie Hopkins Ruled the World (6 August 2015) – 1 episode Kendra on Top (21 August 2015) – 1 episode Keep It in the Family (22 August 2015) – 1 episode Safeword (27 August 2015) – 1 episode Tina Malone: My New Body (1 October 2015) – 1 episode Tricked (27 October 2015) – 1 episode The Wright Stuff (4 February 2016) – 1 episode Virtually Famous (8 March 2016) – 1 episode In Therapy (5 July 2016) – 1 episode It's Not Me, It's You (29 July 2016) – 1 episode Sky News (25 October 2016, 6 September 2024) – 2 episodes Alan Carr's Specstacular (31 December 2016) – 1 episode Through the Keyhole (4 February 2017) – 1 episode BBC Radio 1 Teen Awards (22 October 2017, 21 October 2018) Celebrity 100% Hotter (25 January 2018) – 1 episode The Generation Game (1 April 2018) – 1 episode Livin' with Lucy (10 September 2018) – 1 episode ReFreshers Week Presented By Strongbow (1 October 2018) – 1 episode Your Face or Mine? (3 October 2018) – 1 episode Good Morning Britain (30 October 2018, 19 December 2018, 4 February 2019, 1 April 2019, 24 June 2019, 7 August 2019, 13 November 2019, 25 November 2019, 8 December 2020) – 9 episodes I'll Get This (4 December 2018) – 1 episode Lorraine (4 January 2019, 18 January 2019, 23 January 2019, 8 March 2019, 9 September 2019, 30 September 2019, 15 November 2019, 11 December 2023) – 8 episodes The Jonathan Ross Show (9 March 2019) – 1 episode The Real Housewives of Cheshire (22 April 2019, 11 November 2019) – 2 episodes The Crystal Maze (21 June 2019) – 1 episode Celebrity Catchphrase (31 August 2019) – 1 episode MTV Cribs UK (16 September 2019, 7 December 2020) – 2 episodes Dancing on Ice at Christmas (22 December 2019) – 1 episode The Big Narstie Show (7 February 2020) – 1 episode Inside Missguided: Made in Manchester (12 August 2020) – 1 episode Rolling In It (15 August 2020) – 1 episode Shopping with Keith Lemon (25 October 2020) – 1 episode Celebrity Supply Teacher (17 November 2020) – 1 episode The Wheel (19 December 2020, 18 December 2021) – 2 episodes Dancing on Ice (24 January 2021) – 1 episode Piers Morgan's Life Stories (11 February 2021) – 1 episode RuPaul's Drag Race UK (18 February 2021) – 1 episode Mel Giedroyc: Unforgivable (23 February 2021) – 1 episode Sophie Ellis-Bextor's Kitchen Disco Danceathon (16 November 2021) – 1 episode Angela Scanlon's Ask Me Anything (27 November 2021) – 1 episode The Weakest Link (23 December 2021) – 1 episode Celebrity MasterChef: Christmas Cook-Off (23 December 2021) – 1 episode The Travel Show (4 February 2022) – 1 episode Springwatch (8 June 2022) – 1 episode The Big Breakfast (20 August 2022, 27 August 2022, 3 September 2022) – 3 episodes The Great Scott TreadMills Challenge (16 November 2022) – 1 episode The Greatest Snowman (26 December 2022) – 1 episode Mwy Na Daffs a Taffs (2 March 2023) – 1 episode Would I Lie to You? (24 March 2023) – 1 episode The Great Stand Up to Cancer Bake Off (26 March 2023) – 1 episode Late Night Lycett (14 April 2023) – 1 episode Steph's Packed Lunch (16 May 2023) – 1 episode The Comedy Roast for SU2C (3 November 2023) – 1 episode Celebrity Antiques Road Trip (28 November 2023) – 1 episode Blankety Blank (23 December 2023) – 1 episode The Underdog: Josh Must Win (3 April 2024) – 1 episode Drama Queens (1 May 2024) – 1 episode Who Do You Think You Are? (26 September 2024) – 1 episode Katy Perry: Night of a Lifetime (21 December 2024) – 1 episode Pointless Celebrities (25 January 2025) – 1 episode ITV Racing: Cheltenham Festival Live (13 March 2025, 12 March 2026) – 2 episodes I'm a Celebrity: Unpacked (17 April 2026, 20 April 2026) – 2 episodes
=== Mechanism of mineralization === Mineralization occurs in two phases: the vesicular phase and the fibrillar phase. Vesicular phase: Matrix vesicles, measuring 30-200 nm in diameter, are released from the apical membrane of osteoblasts into the newly formed bone matrix. These vesicles contain alkaline phosphatase, adenosine triphosphatase (ATPase), and inorganic pyrophosphatase, and act as seeding sites for hydroxyapatite crystal formation through localized enzymatic accumulation of calcium and phosphate. Role of alkaline phosphatase: Osteoblasts secrete alkaline phosphatase, which participates in bone mineralization by hydrolyzing pyrophosphate, an inhibitor of mineralization, thereby increasing local inorganic phosphate availability for hydroxyapatite formation. Crystal propagation: Crystal growth proceeds from initial foci in matrix vesicles to form spheroids, which gradually coalesce to form a network of apatite crystals. As the matrix matures, hydroxyapatite microcrystals are organized into a sophisticated composite within the collagen layer by nucleation in the protein lattice.
== External links == "Remifentanil". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on June 28, 2019. "Remifentanil Hydrochloride". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on August 29, 2021.
Sources: en.wikipedia.org
== Literature == Ashle, Steven (June 2002). "Divide and Vitrify" (PDF). Scientific American. 286 (6): 17–19. Bibcode:2002SciAm.286f..17A. doi:10.1038/scientificamerican0602-17. Retrieved May 10, 2015. Lovgren, Stefan. "Corpses Frozen for Future Rebirth by Arizona Company", March 2005, National Geographic
Carrasco had previously been Castillo's Interior Minister during the Bellido cabinet. On 19 November, Presidential Secretary Bruno Pacheco resigned. Pacheco claimed to be innocent, and said he was resigning to stop the smear campaign against the president.
Proteomic profiling of mouse liver revealed that SIRT5 regulates about 16% of all identified malonyl-lysine sites, the majority of which contain only a single malonylated lysine residue. The proteins regulated in this way are mainly involved in glycolysis, gluconeogenesis, fatty acid oxidation, and the urea cycle. The moderate reduction in malonylation observed upon SIRT5 knockdown in turn suggests the presence of additional, unidentified demalonylases. It has also been proposed that demalonylases and deacetylases function less as dedicated regulatory enzymes and more as part of a protein quality-control mechanism.
=== Memory === Cortisol works with adrenaline (epinephrine) to create memories of short-term emotional events; this is the proposed mechanism for storage of flash bulb memories, and may originate as a means to remember what to avoid in the future. However, long-term exposure to cortisol damages cells in the hippocampus; this damage results in impaired learning.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.